DanCann Pharma is pleased to announce the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.
Pursuant to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for the products, Reduvo Adversa and Qixleef. In addition, the agreement covers Tetra’s OTC product Enjouca.
Reduvo Adversa (dronabinol using a novel mucoadhesive-tablet route of administration) are indicated for the treatment of CINV patients (Chemotherapy-Induced Nausea and Vomiting) and for AIDS-related anorexia associated with weight loss. Qixleef and Enjouca are indicated for the treatment of uncontrolled pain in advanced cancer patients as well as for breakthrough pain.
Dronabinol version
Reduvo Adversa technology will allow DanCann to launch a largely improved dronabinol version in the Nordic countries & Germany. The clinical benefits are numerous including: illimited first-pass metabolism leading to an improved bioavailability and consequently to reduced gastro-intestinal exposure and side-effects. The dosage regimen is likely to become BID as opposed to QID. This new technology signifies important intellectual property.
Qixleef is a botanical cannabinoid-derived medicine, planned to become the first prescription product to be dispensed through pharmacies and prescribed by healthcare professionals. The indications for this product are expected to be for advanced cancer pain and breakthrough pain.
“We have very high expectations for the collaboration with Tetra Bio-Pharma. They have a unique portfolio within the pain management and CINV segments, and we look forward to introducing these lines to our markets. We estimate the first sale to commence during second half of 2021, leaving us sufficient time to prepare our sales organization. DanCann estimates reaching peak sales of DKK 340 - 410 million by 2028, depending on the final outcome and scope of the agreement,” says DanCann Pharma’s CCO, John Morell Frellsen.
According to DanCann Pharma’s CEO, Jeppe Krog Rasmussen: “The industry – and hereby also the patients – have had some challenges and restrictions regarding the Danish Pilot Programme with medical cannabis (non-registered), with this agreement we are now entering into a completely new path around approved pharmaceuticals with cannabinoid-derived medicines, where these restrictions are assumed to be minimal. We are very confident that our respective organizations will deliver impactful therapeutic value to Scandinavian and German patients accompanied by financial success for both DanCann and Tetra.”
For more information:
Dancann Pharma
www.dancann.com